Zymeworks Announces Participation in Upcoming Investor Conference - December 21, 2022
21 Dec 2022
Phase 1ADC
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:
JP Morgan Healthcare Conference. Zymeworks’ management will participate in one-on-one meetings on January 12th and a corporate presentation on January 12th at 10:30 am Pacific Time (PT).
All presentations and webcasts will be available on Zymeworks’ website at .
About Zymeworks Inc.
Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks’ proprietary Azymetric™ technology, which is expected to be commercialized globally by two partners: BeiGene in Asia Pacific (APAC) regions excluding Japan, and Jazz Pharmaceuticals globally excluding APAC. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and pivotal clinical trials as a best-in-class treatment for patients with HER2-expressing cancers. Zymeworks' next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates (ADC) and multispecific antibody therapeutics (MSAT). In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been further leveraged and validated in product development through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit and follow @ZymeworksInc on Twitter.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.